Colestipol Hydrochloride and Latanoprost

• Generic Name: colestipol
• Dosage Forms: n.a.
• Other Brand Names: Colestid, Colestid Flavored

Adjunct to dietary therapy to decrease elevated serum total and LDL-cholesterol concentrations in the management of primary hypercholesterolemia in patients who do not respond adequately to diet.

Generally has no clinically relevant effect on serum triglyceride concentrations, but may increase triglyceride concentrations in some patients. (See Hypertriglyceridemia under Cautions.) Do not use in patients with primary dysbetalipoproteinemia (Fredrickson type III).

As effective as cholestyramine in lowering serum cholesterol concentrations. Select bile acid sequestrant based on patient tolerance, including palatability and taste preference, and cost.

ACC/AHA cholesterol management guideline states that nonstatin drugs (e.g., bile acid sequestrants) do not provide acceptable atherosclerotic cardiovascular disease (ASCVD) risk reduction benefits compared to their potential for adverse effects in the routine prevention of ASCVD. May be useful as adjuncts to statin therapy in high-risk patients (e.g., patients with ASCVD, LDL-cholesterol concentrations ≥190 mg/dL, or diabetes mellitus) who have a less-than-anticipated response to statins, are unable to tolerate even a less-than-recommended intensity of a statin, or are completely intolerant to statin therapy. Select nonstatin drug based on favorable benefit-risk ratio (i.e., demonstrated benefit of ASCVD risk reduction outweighs risks of adverse effects and drug interactions) and patient preferences.

• Generic Name: latanoprost ophthalmic
• Dosage Forms: n.a.
• Other Brand Names: Xalatan, Xelpros, Xalatan Multi-Pack

Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. One of several first-line agents to reduce elevated IOP.

Safety and efficacy not established for the treatment of angle-closure, inflammatory, or neovascular glaucoma.

Appears to be more effective than unoprostone, as effective as travoprost, and slightly less effective than bimatoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension.

May be more effective or at least as effective as twice daily administration of timolol 0.5% in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Appears to be more effective than thrice-daily administration of dorzolamide 2%.

May be used in conjunction with a topical β-adrenergic blocking agent (e.g., betaxolol, carteolol, levobunolol, metipranolol, timolol), topical dipivefrin, topical epinephrine, an oral carbonic anhydrase inhibitor (e.g., acetazolamide), or a topical carbonic anhydrase inhibitor (e.g., dorzolamide).

Tolerance does not occur, and reduction in mean IOP is maintained for up to at least 24 months of therapy after initial stabilization.